Abstract: A meeting summarization method, system, and computer program product, include compiling notes from a meeting between a plurality of users and providing a single document that summarizes the meeting based on the compiled notes.

Abstract: Systems and methods are disclosed for estimating slipperiness of a road surface. This estimate may be obtained using an image sensor mounted on a vehicle. The estimated road slipperiness may be utilized when calculating a risk index for the road, or for an area including the road. If a predetermined threshold for slipperiness is exceeded, corrective actions may be taken. For instance, warnings may be generated to human drivers that are in control of driving vehicle, and autonomous vehicles may automatically adjust vehicle speed based upon road slipperiness detected.

Abstract: The present invention provides compositions comprising microbe-targeting molecules (MTMs) that bind microbe-associated molecular patterns, and methods of using the compositions in the prevention and treatment of infectious disease.

Abstract: The present invention provides biological molecules for use in detecting, identifying and/or removing microbes and microbial components; diagnostic, therapeutic and filtration devices comprising the biological molecules; and systems and methods for treating fluids using the biological molecules and devices of the invention.

Abstract: Detection devices comprising microbe-targeting molecules (MTMs) and engineered MTMs in the form of a lateral flow assay (LFA) are provided. Methods of using the detection devices in the detection and/or identification of microbes and microbe components in a sample are also provided.

Abstract: The present invention provides mannose-binding lectin (MBL)-based compositions, and methods of using the MBL-based compositions in the reduction of unintended platelet activation, such as during a medical procedure.

Abstract: Compositions, devices and methods for capturing, detecting and identifying one or more microbes or microbe components and/or treating infectious disease using microbe-targeting molecules (MTMs) are provided.

Abstract: The present invention provides biological molecules for use in detecting, identifying and/or removing microbes and microbial components; diagnostic, therapeutic and filtration devices comprising the biological molecules; and systems and methods for treating fluids using the biological molecules and devices of the invention.

Abstract: It is disclosed here a method for reducing phosphate absorption in a human or non-human animal subject wherein the subject consumes a diet containing phytic acid or phytate and either has or is at risk of developing hyperphosphatemia. The method includes the step of administering orally to the subject an anti-intestinal alkaline phosphatase antibody in an amount effective to reduce or maintain the serum phosphate concentration in the subject.

Abstract: A method for reducing phosphate absorption in a human or non-human animal subject at risk of developing or having developed hyperphosphatemia is disclosed. The method includes the step of administering orally to the subject an anti-intestinal sodium phosphate cotransporter type 2B (Npt2B) antibody in an amount effective to reduce or maintain the serum phosphate concentration in the subject.

Abstract: It is disclosed here a method for reducing phosphate absorption in a human or non-human animal subject wherein the subject consumes a diet containing phytic acid or phytate and either has or is at risk of developing hyperphosphatemia. The method includes the step of administering orally to the subject an anti-intestinal alkaline phosphatase antibody in an amount effective to reduce or maintain the serum phosphate concentration in the subject.

Abstract: A method for reducing phosphate absorption in a human or non-human animal subject at risk of developing or having developed hyperphosphatemia is disclosed. The method includes the step of administering orally to the subject an anti-intestinal sodium phosphate cotransporter type 2B (Npt2B) antibody in an amount effective to reduce or maintain the serum phosphate concentration in the subject.

Abstract: A tandem mass spectrometer and method for calibrating a tandem mass spectrometer. The tandem mass spectrometer comprises first and second mass analyzers. The first and second mass analyzers form an ion path. The second mass analyzer is positioned downstream from the first mass analyzer and is arranged to receive ions from the first mass analyzer. An electrode arrangement positioned between the first and second mass analyzers. The electrode assembly is configured to selectively deflect ions from the ion path.

Abstract: An application and method for disinfecting HVAC systems that includes features for protecting service personnel from unintended exposure to ultraviolet radiation. The safeguards include an interlock that prevents illumination of germicidal lamps when their enclosure case is not properly attached to a duct.

Abstract: A tandem mass spectrometer and method for calibrating a tandem mass spectrometer. The tandem mass spectrometer comprises first and second mass analyzers. The first and second mass analyzers form an ion path. The second mass analyzer is positioned downstream from the first mass analyzer and is arranged to receive ions from the first mass analyzer. An electrode arrangement positioned between the first and second mass analyzers. The electrode assembly is configured to selectively deflect ions from the ion path.

Abstract: A controlled-release pharmaceutical formulation including cholecalciferol and/or ergocalciferol, a method of making the formulation, and a method of administering the formulation to treat 25-hydroxyvitamin D insufficiency or deficiency, are disclosed. The composition and method of administration preferably result in delayed release of the vitamin(s) in the ileum of the small intestine and sustained, substantially constant, release of the vitamin(s) over an extended period, e.g., at least 4 hours or more. Individual and combined dosages of 500 IU to 50,000 IU per dosage form, preferably daily, are disclosed.

Abstract: A system and a method for keying lamps which involve a lamp keying device such as a keying device with at least one base protruding key being formed on the base and at least one support slot being formed in the lamp support receptacle, the at least one base protruding key detachably coupling with the at least one support slot; a keying device with at least one support protruding key being formed on the lamp support receptacle and at least one base slot being formed in the base, the at least one base slot detachably coupling with the at least one protruding support key; and a keying device with at least one base protruding key being formed on the base and at least one base slot being formed in the base, the keying device further having at least one complementary support protruding key being formed on the lamp support receptacle and at least one complementary support slot being formed in the lamp support receptacle, the at least one base protruding key detachably coupling with the at least one complementary sup

Abstract: The present invention relates to the use of sigma-2 agonists to potentiate the activity of antineoplastic agents. These substances are useful for treating cancerous tumors and, in particular, drug resistant tumors in humans. Methods for sensitizing multidrug resistant cells to antitumor agents comprising contact the cells with a sigma-2 agonist are also described.

Abstract: An application and method for disinfecting HVAC systems that includes features for protecting service personnel from unintended exposure to ultraviolet radiation. The safeguards include an interlock that prevents illumination of germicidal lamps when their enclosure case is not properly attached to a duct.

Abstract: A device (20) for Disinfection of HVAC Systems that include features that will protect service personnel from un-intended exposure to ultra violet radiation. The safeguards include an interlock (70) that prevents illumination of germicidal lamps (80) when an enclosure within which the germicidal lamps (80) are mounted is not properly attached to a duct or appliance; the apparatus further provides for innovative methods for determining that the germicidal lamps (80) are operating.